| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | ZTS Zoetis Inc. | Peck Kristin C66 | Chief Executive Officer | Sell | 13,000 | $187.20 | $2,433,636.40 | -14.1% | -6.5% | -16.0% | |
| Feb 20, 2024 | INM Inmed Pharmaceuticals Inc. | Adams Eric A | President &CEO | Buy | 41,600 | $0.36 | $14,921.92 | +1,763% | -13.3% | -55.7% | |
| Feb 20, 2024 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 923 | $187.30 | $172,877.90 | -5.3% | -6.5% | -16.0% | |
| Feb 20, 2024 | NBIX Neurocrine Biosciences Inc | Pops Richard F57 | Director | Sell | 15,000 | $132.47 | $1,987,047.00 | -33.7% | +6.8% | -13.9% | |
| Feb 20, 2024 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 60,000 | $0.08 | $4,740.00 | - | - | - | |
| Feb 16, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 173,261 | $13.05 | $2,261,905.03 | -100.0% | +25.2% | +24.8% | |
| Feb 16, 2024 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 50,000 | $0.07 | $3,500.00 | +10.0% | - | - | |
| Feb 16, 2024 | JNJ Johnson & Johnson | Johnson & Johnson59 | 10% Owner | Sell | 3,725 | $25.81 | $96,142.25 | - | -1.5% | -0.3% | |
| Feb 16, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 169,684 | $780.99 | $132,521,930.24 | - | -1.4% | +8.0% | |
| Feb 15, 2024 | VTRS Viatris Inc | Cuneo Andrew49 | See Remarks | Sell | 4,000 | $12.50 | $50,000.00 | -9.3% | -13.7% | -15.8% | |
| Feb 15, 2024 | ALKS Alkermes Plc. | Laurencin Cato T59 | Director | Sell | 2,690 | $31.85 | $85,676.50 | -15.1% | -25.9% | +10.2% | |
| Feb 15, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Francis Richard D | President And CEO | Sell | 74,530 | $13.15 | $980,173.84 | -46.1% | +27.1% | +23.1% | |
| Feb 15, 2024 | PBH Prestige Consumer Healthcare Inc. | Mekhail Adel48 | EVP, Marketing &Sales | Sell | 15,549 | $69.11 | $1,074,644.92 | -29.4% | -3.4% | +25.0% | |
| Feb 15, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 50,316 | $760.46 | $38,263,417.08 | - | +3.9% | +11.4% | |
| Feb 15, 2024 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $215.31 | $1,291,884.86 | -4.9% | +27.1% | +72.7% | |
| Feb 15, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 23,081 | $10.01 | $231,033.95 | -7.0% | +37.7% | +501.7% | |
| Feb 14, 2024 | PBH Prestige Consumer Healthcare Inc. | Sacco Christine | Chief Financial Officer | Sell | 30,019 | $68.35 | $2,051,873.56 | -39.2% | +5.6% | +26.6% | |
| Feb 14, 2024 | PBH Prestige Consumer Healthcare Inc. | P'pool William54 | See Remarks | Sell | 26,019 | $67.90 | $1,766,665.29 | -34.3% | +5.6% | +26.6% | |
| Feb 14, 2024 | MRK Merck & Co., Inc. | Litchfield Caroline | EVP &CFO | Sell | 38,291 | $125.50 | $4,805,520.50 | -42.9% | +2.9% | -31.1% | |
| Feb 14, 2024 | MRK Merck & Co., Inc. | Davis Robert M46 | Chairman, CEO &President | Sell | 235,021 | $125.69 | $29,538,998.07 | -18.0% | +2.9% | -31.1% | |
| Feb 14, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew48 | Chief Executive Officer | Sell | 256,131 | $9.80 | $2,511,317.25 | -62.3% | +37.5% | +492.4% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 1,352 | $132.89 | $179,673.63 | -1.0% | +1.7% | -12.4% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 1,114 | $132.96 | $148,121.78 | -4.5% | +1.7% | -12.4% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 1,811 | $133.07 | $240,995.73 | -14.5% | +1.7% | -12.4% | |
| Feb 13, 2024 | MRK Merck & Co., Inc. | Romanelli Joseph57 | President, Human Health Int?l | Sell | 1,000 | $124.89 | $124,887.90 | -4.9% | +3.7% | -29.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.